BRKR

Bruker Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Other Science, Medical Devices, Research, Nanotechnology, Science, Hardware, Corporation, PIN, BEST, BRKR, CER, FY, Bruker, Growth, Conference, Webcast, BSI, Acquisition, EPS, Infection, Telephone, GAAP, Pharmaceutical industry

Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2024.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2024.
  • First quarter 2024 Bruker Scientific Instruments (BSI) segment revenues of $651.1 million increased 3.9% yoy, with organic revenue flat.
  • First quarter 2024 Bruker Energy & Supercon Technologies (BEST) segment revenues of $73.1 million increased 17.5% yoy, with organic revenue growth, net of intercompany eliminations, of 18.9%.
  • Bruker will host a conference call and webcast to discuss its financial results, business outlook, and related corporate and financial matters today, May 2, 2024, at 8:30 am Eastern Standard Time.

Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast

Retrieved on: 
Thursday, April 25, 2024
Biotechnology, Technology, Health, Pharmaceutical, Semiconductor, Health Technology, Research, Artificial Intelligence, Nanotechnology, Science, Electronic Design Automation, BRKR, Bruker, Telephone, Corporation, Conference, Webcast, PIN, Broadcasting

Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024.
  • To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2024 Earnings Webcast” hyperlink in the “Events & Presentations” section.
  • A slide presentation will be referenced during the webcast and will be posted to the Company’s website shortly before the webcast begins.
  • Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s First Quarter 2024 Earnings Conference Call”.

Bruker to Acquire the NanoString Business in an Asset Deal

Retrieved on: 
Monday, April 22, 2024
Research, Finance, Genetics, Banking, Professional Services, Biotechnology, Health, Other Science, Science, Goldman Sachs, Sale, Corporation, BRKR, NanoString Technologies, Gene expression profiling, Hand, AlixPartners, Willkie Farr & Gallagher, Acquisition, EPS, Morgan, Lewis & Bockius, Growth, Fine chemical

Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString’s business, including the nCounter®, GeoMx®, CosMx™ and AtoMx™ product lines, for approximately $392.6 million in cash, and the assumption of certain liabilities.

Key Points: 
  • Under the asset purchase agreement, Bruker expects to acquire substantially all of the assets and rights associated with NanoString’s business, including the nCounter®, GeoMx®, CosMx™ and AtoMx™ product lines, for approximately $392.6 million in cash, and the assumption of certain liabilities.
  • NanoString is a provider of life science tools for discovery and translational research with leading solutions for spatial transcriptomics and gene expression analysis.
  • Following the closing, the NanoString business will become part of the Bruker Spatial Biology business.
  • By 2026, Bruker expects the NanoString business to have rebounded and to be near break-even with resumed revenue growth and margin improvements, also taking advantage of deal synergies, as Bruker is not acquiring NanoString’s public company overhead in this asset deal.

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Retrieved on: 
Monday, April 8, 2024
Research, Technology, Semiconductor, Genetics, Health Technology, Nanotechnology, Biotechnology, Hardware, Health, Science, CNRS, CPMAS, 2000s, HCN, Membrane, Corporation, DNP, NMR, Bruker, Hertz, Protein, Multimedia, MAS, BRKR, WB, Medical imaging

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.
  • Featuring a 160 kHz Magic Angle Spinning (MAS) system, it takes high-resolution MAS and proton detection on solid biological samples to the next level, enabling new scientific discoveries.
  • The dramatically enhanced 1H-NMR resolution and enhanced T2' times make 160 kHz MAS suitable for the study of large proteins, membrane proteins and protein aggregates.
  • In addition, a 160 kHz MAS probe is now installed on the 1.0 GHz NMR at CNRS Lyon, where it expands the scientific capabilities of biological solid-state research.

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Semiconductor, Research, Data Analytics, Software, Science, Hardware, Quality control, Evo, Corporation, NMR, Active ingredient, Bruker, AI, Ascend, PAT, API, Safety, Magnet, Hertz, Machine learning, Multimedia, Fourier, BRKR, Medical imaging

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
  • The new Ascend Evo 600 magnet is easier to site, has reduced installation and operational costs, and has lower Helium consumption compared to previous 600 MHz magnets.
  • In addition, Bruker expands the applications of its Fourier 80 platform, a benchtop 80 MHz Fourier Transform NMR with a high-performance permanent magnet that requires no cryogens or power.
  • Here, the Fourier 80 system gathers reaction data for AI machine learning to formulate the rules and actions to guide process optimization.

Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook

Retrieved on: 
Monday, April 1, 2024
Health, Science, Other Science, Research, Medical Supplies, CER, Culture, Growth, Project, EPS, Corporation, Spiral Dynamics, Operational excellence, Proteomics, BRKR

Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023.

Key Points: 
  • Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook (IBO) ‘Company of the Year’ for 2023.
  • IBO cited Bruker’s double-digit organic revenue growth in 2023 in all major regions, and in all business groups, demonstrating a transformed portfolio and operational strength.
  • The IBO recognition follows Bruker’s three consecutive years of double-digit organic revenue growth.
  • IBO is a publication of SDi, a division of Science and Medicine Group, which offers custom market research and strategic advisory services.

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Retrieved on: 
Monday, March 11, 2024
Software, Research, Hardware, Pharmaceutical, Oncology, Technology, Medical Devices, Infectious Diseases, Genetics, Health Technology, Science, Biotechnology, Health, QC, GPU, Utrecht University, Pharmacy, IRT, Drug discovery, Radboud University Nijmegen, Cell biology, Biomarker, Molecular genetics, Bruker, University, Ultra, University of Michigan, Proteomics, Peptide, Infection, Pulse, Neoplasm, Glycomics, Lunenfeld-Tanenbaum Research Institute, TIMS, Multimedia, Medical director, BRKR, Pathology, Medical device

At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.

Key Points: 
  • At the 20th US Human Proteome Organization Congress 2024, Bruker Corporation (Nasdaq: BRKR) announced progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows.
  • The rapid advances in deep, at-scale proteomics, glycomics and peptidomics research solutions complement other performance-leading life-science tools for the post-genomic era by Bruker.
  • Bruker enhances its timsTOF HT and timsTOF Ultra systems with the new software Novor v2.0 for de novo immunopeptidomic profiling.
  • Our software suite supports the analysis of PASEF data, and we are delighted that Bruker now offers it with timsTOF instruments.

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Other Science, Research, Science, Biotechnology, Acquisition, Hospital, Infection, Cystic fibrosis, Microbiology, MALDI, Mycobacterium, MDX, Fungal infection, PAI Partners, PAI, COVID, BRKR, Tuberculosis, Hand, Corporation, PCR, HIV, IVD, Partnership

This put option has now been exercised, and the parties have entered into a binding share purchase agreement.

Key Points: 
  • This put option has now been exercised, and the parties have entered into a binding share purchase agreement.
  • ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products.
  • Establishing this unique business within Bruker - a well-respected global life-science tools and specialty diagnostics company - provides an exciting opportunity to further grow our molecular diagnostics, microbiology and biomedical systems portfolios.
  • Upon closing, ELITech is expected to be a stand-alone business within Bruker’s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

Bruker Corporation to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 26, 2024
Technology, Research, Medical Devices, Other Technology, Nanotechnology, Health Technology, Biotechnology, Health, Science, CFO, Corporation, Conference, Bruker, BRKR

Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:
    TD Cowen 44th Annual Health Care Conference in Boston, MA
    Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com .
  • Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the events and will be available for 90 days following the presentations.

Bruker Announces Quarterly Dividend

Retrieved on: 
Friday, February 16, 2024
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Electronic Design Automation, Technology, Corporation, Bruker, BRKR

Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on March 15, 2024 to stockholders of record as of March 1, 2024.

Key Points: 

Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on March 15, 2024 to stockholders of record as of March 1, 2024.